PropertyValue
?:definition
  • An orally available inhibitor of the receptor tyrosine kinases AXL (UFO) and c-MET/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Upon administration, AXL/c-MET receptor tyrosine kinase inhibitor BPI-9016M, binds to both AXL and c-MET, thereby disrupting both AXL- and c-MET-mediated signaling pathways. Altogether, this agent inhibits growth in AXL- and c-MET-overexpressing tumor cells. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases, and c-MET, both overexpressed by many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis. Check for \'https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C132025\' active clinical trials using this agent. (\'http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C132025\' NCI Thesaurus)
?:hasCUIAnnotation
?:hasGeneratedBy
?:type

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/C4329233_PDQ>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/C4329233_PDQ>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all